ACI 35

Drug Profile

ACI 35

Alternative Names: Anti-pTau vaccine - AC Immune

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AC Immune
  • Developer AC Immune; Janssen Pharmaceuticals
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 30 Jun 2017 AC Immune completes a phase I trial in Alzheimer's disease in Finland and United Kingdom (ISRCTN13033912)
  • 17 Mar 2017 Phase-I clinical trials in Alzheimer's disease in Finland (Parenteral) before March 2017
  • 12 Jan 2015 Janssen Pharmaceuticals acquires worldwide exclusive licence to ACI 35 from AC Immune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top